Literature DB >> 23054134

Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics.

Shaomeng Wang1, Longchuan Bai, Jianfeng Lu, Liu Liu, Chao-Yie Yang, Haiying Sun.   

Abstract

Apoptosis resistance is a hallmark of human cancer. Research in the last two decades has identified key regulators of apoptosis, including inhibitor of apoptosis proteins (IAPs). These critical apoptosis regulators have been targeted for the development of new cancer therapeutics. In this article, we will discuss three members of IAP proteins, namely XIAP, cIAP1 and cIAP2, as cancer therapeutic targets and the progress made in developing new cancer therapeutic agents to target these IAP proteins.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23054134      PMCID： PMC3534930          DOI： 10.1007/s10911-012-9265-1

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN： 1083-3021            Impact factor:   2.673


  51 in total

1.  Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination.

Authors:  Erin C Dueber; Allyn J Schoeffler; Andreas Lingel; J Michael Elliott; Anna V Fedorova; Anthony M Giannetti; Kerry Zobel; Brigitte Maurer; Eugene Varfolomeev; Ping Wu; Heidi J A Wallweber; Sarah G Hymowitz; Kurt Deshayes; Domagoj Vucic; Wayne J Fairbrother
Journal:  Science       Date:  2011-10-21       Impact factor: 47.728

2.  Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner.

Authors:  B L Probst; L Liu; V Ramesh; L Li; H Sun; J D Minna; L Wang
Journal:  Cell Death Differ       Date:  2010-04-30       Impact factor: 15.828

3.  Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization.

Authors:  Rebecca Feltham; Bodhi Bettjeman; Rhesa Budhidarmo; Peter D Mace; Sarah Shirley; Stephen M Condon; Srinivas K Chunduru; Mark A McKinlay; David L Vaux; John Silke; Catherine L Day
Journal:  J Biol Chem       Date:  2011-03-10       Impact factor: 5.157

4.  Prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype.

Authors:  Jinjing Wang; Yixin Liu; Ru Ji; Qiang Gu; Xiulan Zhao; Yanrong Liu; Baocun Sun
Journal:  Hum Pathol       Date:  2010-04-10       Impact factor: 3.466

5.  LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.

Authors:  Longchuan Bai; Donna McEachern; Chao-Yie Yang; Jianfeng Lu; Haiying Sun; Shaomeng Wang
Journal:  Cancer Res       Date:  2012-01-12       Impact factor: 12.701

6.  A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

Authors:  Qian Cai; Haiying Sun; Yuefeng Peng; Jianfeng Lu; Zaneta Nikolovska-Coleska; Donna McEachern; Liu Liu; Su Qiu; Chao-Yie Yang; Rebecca Miller; Han Yi; Tao Zhang; Duxin Sun; Sanmao Kang; Ming Guo; Lance Leopold; Dajun Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2011-03-28       Impact factor: 7.446

Review 7.  Targeting IAP proteins for therapeutic intervention in cancer.

Authors:  Simone Fulda; Domagoj Vucic
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

8.  Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).

Authors:  John A Flygare; Maureen Beresini; Nageshwar Budha; Helen Chan; Iris T Chan; Sravanthi Cheeti; Frederick Cohen; Kurt Deshayes; Karl Doerner; S Gail Eckhardt; Linda O Elliott; Bainian Feng; Matthew C Franklin; Stacy Frankovitz Reisner; Lewis Gazzard; Jason Halladay; Sarah G Hymowitz; Hank La; Patricia LoRusso; Brigitte Maurer; Lesley Murray; Emile Plise; Clifford Quan; Jean-Philippe Stephan; Shin G Young; Jeffrey Tom; Vickie Tsui; Joanne Um; Eugene Varfolomeev; Domagoj Vucic; Andrew J Wagner; Heidi J A Wallweber; Lan Wang; Joseph Ware; Zhaoyang Wen; Harvey Wong; Jonathan M Wong; Melisa Wong; Susan Wong; Ron Yu; Kerry Zobel; Wayne J Fairbrother
Journal:  J Med Chem       Date:  2012-03-28       Impact factor: 7.446

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 10.  IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer.

Authors:  Mads Gyrd-Hansen; Pascal Meier
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716
View more
  13 in total

1.  A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice.

Authors:  Rong Sheng; Haiying Sun; Liu Liu; Jianfeng Lu; Donna McEachern; Guanfeng Wang; Jianfeng Wen; Ping Min; Zhenyun Du; Huirong Lu; Sanmao Kang; Ming Guo; Dajun Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2013-05-07       Impact factor: 7.446

2.  Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.

Authors:  Nobumichi Ohoka; Yoko Morita; Katsunori Nagai; Kenichiro Shimokawa; Osamu Ujikawa; Ikuo Fujimori; Masahiro Ito; Youji Hayase; Keiichiro Okuhira; Norihito Shibata; Takayuki Hattori; Tomoya Sameshima; Osamu Sano; Ryokichi Koyama; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  J Biol Chem       Date:  2018-03-15       Impact factor: 5.157

3.  Critical tumor suppressor function mediated by epithelial Mig-6 in endometrial cancer.

Authors:  Tae Hoon Kim; Dong-Kee Lee; Sung-Nam Cho; Grant D Orvis; Richard R Behringer; John P Lydon; Bon Jeong Ku; Adrienne S McCampbell; Russell R Broaddus; Jae-Wook Jeong
Journal:  Cancer Res       Date:  2013-06-27       Impact factor: 12.701

Review 4.  Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.

Authors:  Federica Begalli; Jason Bennett; Daria Capece; Daniela Verzella; Daniel D'Andrea; Laura Tornatore; Guido Franzoso
Journal:  Biomedicines       Date:  2017-08-22

5.  Development of XIAP Antagonists Based On De Novo 8,5-Fused Bicyclic Lactams.

Authors:  Zhaojun J Sheng; Yiming M Shi; Ximing Xu; Sébastien Bellynck; Kun Zhang; Zhiyun Y Du; Xuetao Xu; François Maurel; Chang-Zhi Dong
Journal:  ChemistryOpen       Date:  2019-01-15       Impact factor: 2.911

6.  Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.

Authors:  Pierre-Simon Bellaye; Alexandra Oudot; Jean-Marc Vrigneaud; Olivier Raguin; Francis Bichat; Anne Vaslin; Hélène Maby-El Hajjami; Claudio Zanna; Grégoire Vuagniaux; Pierre Fumoleau; Franck Denat; François Brunotte; Bertrand Collin
Journal:  Contrast Media Mol Imaging       Date:  2018-12-02       Impact factor: 3.161

Review 7.  Long Noncoding RNA GAS5 in Breast Cancer: Epigenetic Mechanisms and Biological Functions.

Authors:  Elena A Filippova; Marina V Fridman; Alexey M Burdennyy; Vitaly I Loginov; Irina V Pronina; Svetlana S Lukina; Alexey A Dmitriev; Eleonora A Braga
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

8.  Tea polyphenols induced apoptosis of breast cancer cells by suppressing the expression of Survivin.

Authors:  Xuesong Chen; Yu Li; Qiushi Lin; Yan Wang; Hong Sun; Jian Wang; Guoquan Cui; Li Cai; Xiaoqun Dong
Journal:  Sci Rep       Date:  2014-03-20       Impact factor: 4.379

9.  Livin serves as a prognostic marker for mid-distal rectal cancer and a target of mid-distal rectal cancer treatment.

Authors:  Qi-Biao Su; Lai-You Wang; Gui-Ning Wei; Li-Zhen Liao; Jie Zhao; Hong-Jun Liu; Yu-Long Shi; Le-Ping Li; Chen-Sheng Li
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

10.  Inhibitor of apoptosis protein‑like protein‑2: A novel growth accelerator for breast cancer cells.

Authors:  Lin Zhu; Weihua Zhou; Xidi Zhu; Siqi Xiang; Siyuan Wang; Yingxia Peng; Bangyun Lu; Peizhi Tang; Qian Chen; Mengjuan Wu; Xia Peng; Ziyu Chen; Ziyi Sun; Kunliang Yang; Mingjun Xiang; Dandan Yu
Journal:  Oncol Rep       Date:  2018-08-03       Impact factor: 3.906
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.